Cisplatin in Liver Cancer Therapy

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(13), С. 10858 - 10858

Опубликована: Июнь 29, 2023

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and often diagnosed at an unresectable advanced stage. Systemic chemotherapy as well transarterial chemoembolization (TACE) hepatic arterial infusion (HAIC) are used to treat HCC. TACE HAIC have long been standard of care for patients with HCC but limited treatment intrahepatic lesions. doxorubicin or chemohormonal therapy tamoxifen also considered, neither has demonstrated survival benefits. In HCC, cisplatin administered transhepatic arterially local treatment. Subsequently, cisplatin-refractory cases due drug resistance, a shift systemic different mechanism action expected produce new antitumor effects. Cisplatin tumors other than This review summarizes resistance describes major hepatobiliary cancers which anticancer agent, focus on

Язык: Английский

---

Epidemiology of cholangiocarcinoma

European Journal of Surgical Oncology, Год журнала: 2023, Номер unknown, С. 107064 - 107064

Опубликована: Сен. 1, 2023

Cholangiocarcinoma (CCA) represents a heterogenous set of malignancies arising from the biliary tract. Classification CCA subdivides tumours into intrahepatic (iCCA) and extrahepatic (eCCA), with eCCA further categorised as perihilar (pCCA) distal (dCCA) lesions. Tumour subtypes show distinct epidemiological, genetic clinical characteristics. Global incidence mortality are rising, highest rates seen in Asian populations compared to West. There has been divergence recent trends observed between subtypes, rising iCCA eCCA. several drivers for these differing trends, including specific risk factors, misclassification variation diagnosis surveillance. Risk factors can be divided hepatobiliary, extra-hepatic environmental, hepatobiliary diseases conferring largest risk. Surgery only curative treatment CCA, but offered early-stage candidates who otherwise fit; majority patients therefore treated chemotherapy and, recently, immunotherapy. Due late-stage presentation disease, prognosis is poor, 5-year survival <20%.

Язык: Английский

---

Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019

International Journal of Cancer, Год журнала: 2023, Номер 154(4), С. 615 - 625

Опубликована: Сен. 26, 2023

The burden of digestive cancers is increasing worldwide. Global Cancer Observatory (GLOBOCAN) 2020 and the Burden Disease (GBD) 2019 are two primary cancer databases, which have a significant impact on policy formulation resource allocation. We aim to compare incidence mortality between them. Digestive (esophageal, stomach, colorectal, liver, gallbladder pancreatic cancer) was obtained from Today GBD result tool. top five countries with most or minor difference GLOBOCAN in age-standardized rates (ASIRs) were identified. A systematic search specific selected PubMed Embase conducted, 20 281 publications included. differences commonly found Asian (70%), particularly Indonesia, Vietnam Myanmar, located Southeast Asia. ASIRs for cancers, except liver cancer, higher than those 2019. Gallbladder had highest average ratio, followed by cancer. used standard population Segi's population, World Health Organization population. data sources nor processing methods not similar. Low- middle-income without population-based registries more likely selection bias collection amplify regional variations etiological factors. Better judgments quality can be made.

Язык: Английский

---

British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma

Gut, Год журнала: 2023, Номер 73(1), С. 16 - 46

Опубликована: Сен. 28, 2023

These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by British Society Gastroenterology liver section. The guideline writing committee included a multidisciplinary team experts from various specialties involved in CCA, as well patient/public representatives AMMF (the Cholangiocarcinoma Charity) PSC Support. Quality evidence is presented using Appraisal Guidelines Research Evaluation (AGREE II) format. recommendations arising are to be used guidance rather than strict protocol-based reference, patients with CCA often complex always requires individual patient-centred considerations.

Язык: Английский

---

Mapping the landscape of biliary tract cancer in Europe: challenges and controversies

The Lancet Regional Health - Europe, Год журнала: 2025, Номер 50, С. 101171 - 101171

Опубликована: Фев. 19, 2025

Biliary tract cancer (BTC) is becoming more common worldwide, with geographic differences in incidence and risk factors. In Europe, BTC may be associated primary sclerosing cholangitis, lithiasis, liver cirrhosis, but frequently observed as a sporadic disease. increasingly affects patients under 60 years, resulting significant social economic burden. Early diagnosis remains challenging due to vague symptoms 50% of BTC, lack specific biomarkers, late presentation poor prognosis. The identification at increased reliable biomarkers require collaborative efforts make faster progress. This Series paper highlights the disparities access diagnostic tools multidisciplinary care particularly economically disadvantaged regions, while identifying priority areas for improvement. Addressing these inequities requires harmonised guidelines, accelerated pathways curative treatments, improved awareness among healthcare professionals public. Multidisciplinary teams (MDTs) are crucial improving patient outcomes, yet inconsistencies exist their implementation not only between different countries, also centres within country. Collaboration standardisation treatment protocols across Europe essential effectively address management BTC.

Язык: Английский

---

New epidemiologic trends in cholangiocarcinoma

Clinics and Research in Hepatology and Gastroenterology, Год журнала: 2023, Номер 47(9), С. 102223 - 102223

Опубликована: Окт. 4, 2023

Язык: Английский

---

Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma

Current Treatment Options in Oncology, Год журнала: 2024, Номер 25(1), С. 127 - 160

Опубликована: Янв. 1, 2024

Biliary tract cancers are molecularly and anatomically diverse which include intrahepatic cholangiocarcinoma, extrahepatic (perihilar distal) gallbladder cancer. While recognized as distinct entities, the rarer incidence of these combined with diagnostic challenges in classifying anatomic origin has resulted clinical trials guideline recommended strategies being generalized patients all types biliary In this review, we delve into unique aspects, subtype-specific trial outcomes, multidisciplinary management cholangiocarcinoma. When resectable, definitive surgery followed by adjuvant chemotherapy (sometimes selective radiation/chemoradiation) is current standard care. Due to high recurrence rates, there growing interest use upfront/neoadjuvant therapy improve surgical outcomes downstage who may not initially be resectable. Select perihilar cholangiocarcinoma successfully treated novel approaches such liver transplant. advanced disease setting, combination gemcitabine cisplatin remains base for systemic was recently improved upon addition immune checkpoint blockade doublet reported TOPAZ-1 KEYNOTE-966 trials. Second-line all-comer treatments remain limited both options efficacy, so participation should strongly considered. With increased molecular testing, detection actionable mutations opportunities receive indicated targeted therapies on rise most significant driver survival stage disease. Though currently reserved second or later line, future looking at moving earlier treatment settings immunotherapy. cross-disciplinary surgical, medical, radiation oncology, patient-centered care also collaboration endoscopists, palliative specialists, nutritionists global patient outcomes.

Язык: Английский

---

90Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry

European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер 51(7), С. 2100 - 2113

Опубликована: Фев. 13, 2024

Evaluation of

Язык: Английский

---

Cuproptosis-related genes score and its hub gene GCSH: A novel predictor for cholangiocarcinomas prognosis based on RNA seq and experimental analyses

Journal of Cancer, Год журнала: 2024, Номер 15(6), С. 1551 - 1567

Опубликована: Янв. 1, 2024

Background: Recent researches have demonstrate that cuproptosis, a copper-dependent cell death mechanism, is related to tumorigenesis, progression, clinical prognosis, tumor microenvironment, and drug sensitivity.Nevertheless, the function impact of cuproptosis in cholangiocarcinoma (CCA), remain elusive.Methods: Utilizing data obtained from Gene Expression Omnibus (GEO) The Cancer Genome Atlas (TCGA-CHOL) datasets, we conducted subgroup typing CCA according cuproptosis-related genes (CRGs) explored functional differences prognostic value between groups.A CRG score was established considering prognosis gene expression.Furthermore, immune response immunotherapy, metabolic patterns, cancer progression characteristics high-and low-risk groups were examined on basis these scores.In vitro experiments validated key glycine cleavage system protein H (GCSH) cellular tissues, respectively.Results: Prognostic models genetic achieved satisfactory results validation.Metabolic-related expression levels microenvironment distribution significantly different high low groups.GCSH revealed as singular (HR =6.04; 95% CI: 1.15-31.80).Moreover, inhibition cupcoptosis GCSH attenuated malignant ability lines vitro, including proliferation, migration invasion, this may be via JAK-STAT signaling CCA. Conclusion:The scoring accurately predicts opens up new possibilities for therapy CCA.The has been preliminarily confirmed reliable therapeutic target or marker patients.

Язык: Английский

---

National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma

World Journal of Gastroenterology, Год журнала: 2024, Номер 30(9), С. 1018 - 1042

Опубликована: Март 5, 2024

A consensus meeting of national experts from all major hepatobiliary centres in the country was held on May 26, 2023, at Pakistan Kidney and Liver Institute & Research Centre (PKLI RC) after initial consultations with experts. The Society for Study Diseases (PSSLD) PKLI RC jointly organised this meeting. This effort based a comprehensive literature review to establish practice guidelines hilar cholangiocarcinoma (hCCA). that hCCA is complex disease requires multidisciplinary team approach best manage these patients. coordinated can minimise delays give patients chance curative treatment effective palliation. diagnostic staging workup includes high-quality computed tomography, magnetic resonance imaging, cholangiopancreatography. Brush cytology or biopsy utilizing endoscopic retrograde cholangiopancreatography mainstay diagnosis. However, histopathologic confirmation not always required before resection. Endoscopic ultrasound fine needle aspiration regional lymph nodes positron emission tomography scan are valuable adjuncts staging. only surgical resection biliary tree Bismuth-Corlette classification. Selected unresectable be considered liver transplantation. Adjuvant chemotherapy should offered high risk recurrence. use preoperative drainage need portal vein embolisation local discussions. Patients acute cholangitis drained percutaneous drainage. Palliative cisplatin gemcitabine has shown improved survival irresectable recurrent hCCA.

Язык: Английский

---